- Home
- EVN vs ERAS Comparison
EVN vs ERAS Comparison
Compare EVN & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVN
- ERAS
- Stock Information
- Founded
- EVN 1998
- ERAS 2018
- Country
- EVN United States
- ERAS United States
- Employees
- EVN N/A
- ERAS N/A
- Industry
- EVN Investment Bankers/Brokers/Service
- ERAS Biotechnology: Pharmaceutical Preparations
- Sector
- EVN Finance
- ERAS Health Care
- Exchange
- EVN Nasdaq
- ERAS Nasdaq
- Market Cap
- EVN 410.0M
- ERAS 432.6M
- IPO Year
- EVN N/A
- ERAS 2021
- Fundamental
- Price
- EVN $10.35
- ERAS $1.23
- Analyst Decision
- EVN
- ERAS Strong Buy
- Analyst Count
- EVN 0
- ERAS 6
- Target Price
- EVN N/A
- ERAS $4.83
- AVG Volume (30 Days)
- EVN 101.2K
- ERAS 1.8M
- Earning Date
- EVN 01-01-0001
- ERAS 03-20-2025
- Dividend Yield
- EVN 4.78%
- ERAS N/A
- EPS Growth
- EVN N/A
- ERAS N/A
- EPS
- EVN 0.34
- ERAS N/A
- Revenue
- EVN N/A
- ERAS N/A
- Revenue This Year
- EVN N/A
- ERAS N/A
- Revenue Next Year
- EVN N/A
- ERAS N/A
- P/E Ratio
- EVN $29.94
- ERAS N/A
- Revenue Growth
- EVN N/A
- ERAS N/A
- 52 Week Low
- EVN $8.64
- ERAS $1.20
- 52 Week High
- EVN $10.45
- ERAS $3.45
- Technical
- Relative Strength Index (RSI)
- EVN 44.77
- ERAS 39.36
- Support Level
- EVN $10.18
- ERAS $1.40
- Resistance Level
- EVN $10.69
- ERAS $1.61
- Average True Range (ATR)
- EVN 0.14
- ERAS 0.11
- MACD
- EVN -0.02
- ERAS 0.01
- Stochastic Oscillator
- EVN 32.35
- ERAS 4.00
About EVN Eaton Vance Municipal Income Trust
Eaton Vance Municipal Income Trust is a United States-based diversified, closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax. The trust's portfolio of investments majorly consists of debt instruments of governments, municipal organizations the interest on which is exempt from regular federal income tax and has also some exposure to corporate bonds and other instruments.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.